Centro Comprensivo De Cancer De La Universidad De Puerto Rico

Centro Comprensivo De Cancer De La Universidad De Puerto Rico, through its Sponsor Programs Division, operates as a U.S. government entity and self-certified small disadvantaged business based in San Juan, Puerto Rico, receiving federal research grants as a prime recipient and sub-recipient in cancer research, prevention, and control programs. The center does not hold federal contracting vehicles and competes in the federal grant space, predominantly under National Institutes of Health (NIH) and Centers for Disease Control and Prevention (CDC) mechanisms.

The center's federal footprint consists of 36 total awards (61% prime grants, 39% sub-awards) with combined obligated dollars of $78.9 million across research and programmatic work. The National Cancer Institute dominates funding concentration, accounting for 21 awards with $94 thousand in combined potential value—substantially all of the center's active portfolio. The National Institute of Dental and Craniofacial Research, the Centers for Disease Control and Prevention, and the Federal Emergency Management Agency account for the remaining five awards. Funding concentration is extreme: the top customer covers 100% of combined potential value, indicating a single-agency dependence profile typical of university-based cancer research centers.

Recent prime grant work includes a $591,360 R01 award from NCI (award date August 27, 2026, performance through July 31, 2031) investigating inherited non-coding variants in the enhancer architecture of breast cancer, with focus on FOXA1 and ancestry-specific protective variants present in indigenous American populations; a CDC cooperative agreement (award date June 30, 2022, performance through June 29, 2027) for the Puerto Rico Cancer Prevention and Control Program and Coordinating Center supporting breast and cervical cancer screening; an NIAID research education program award (August 1, 2024, performance through June 30, 2029) recruiting postbaccalaureate trainees for hands-on research in microbes, infections, and cancer; and an NIEHS project grant (September 20, 2024, performance through August 31, 2027) for the Caribbean Climate Change Adaptation, Cancer, and Health Disparities Research Center addressing climate impacts on cancer control infrastructure in Puerto Rico and the U.S. Virgin Islands. Sub-award engagement includes participation in UC Davis's Latin America Genomics of Breast Cancer Risk Study (January 28, 2026), Columbia University's colorectal cancer organoid development study (January 5, 2024), and University of Wisconsin's Lynch syndrome colorectal cancer vaccine trial (February 15, 2024 and subsequent tasks).

Activity has been volatile: four awards in 2022, one in 2023, nine in 2024, three in 2025, and three in 2026. Four awards reach ultimate completion within the next twenty-four months, triggering recompete exposure. The center's capability portfolio centers on cancer epidemiology, prevention, screening implementation, and translational research with particular emphasis on health disparities in Hispanic and Puerto Rican populations, infrastructure resilience post-disaster, and HPV-related malignancies. Work is performed in Puerto Rico with some multi-site coordination across the Caribbean region and with mainland research institutions.